Arbutus Biopharma Corporation

Arbutus Biopharma Corporation is a dynamic clinical-stage biopharmaceutical company dedicated to the research and development of innovative therapies for infectious diseases. Focused on advancing patient care through cutting-edge science, Arbutus Biopharma Corporation is committed to addressing unmet medical needs in the field of virology. The company's primary address is 701 Veterans Circle, Warminster, Pennsylvania 18974, US.

Arbutus Biopharma Corporation is actively developing a range of promising drug candidates, including imdusiran (AB-729), a GalNAc-conjugated RNAi therapeutic, and AB-101, an oral PD-L1 inhibitor, both aimed at providing effective treatments for chronic hepatitis B virus. Arbutus Biopharma Corporation's strategic approach combines rigorous research with a commitment to delivering impactful solutions for patients worldwide.

With a strong foundation in scientific excellence, Arbutus Biopharma Corporation continues to expand its research programs and collaborations. The company is poised for significant growth and is dedicated to making substantial contributions to the future of infectious disease treatment. We invite the management of Arbutus Biopharma Corporation to create a customized and exclusive company showcase and product listing on our platform to further highlight their advancements and capabilities.